Dr Mark Albertella appointed VP Translational Oncology
20 May 2019, Cambridge, UK: STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, today announced that it has raised an additional
£14 million bringing the total Series A financing to £30 million.
The financing includes funding from new investor, Seroba Life Sciences (“Seroba”). STORM’s existing investors, Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group also participated in the fundraise.
This extension follows the company’s rapid progress to date. It will enable STORM to advance its broad pipeline further in preclinical development and accelerate its programmes towards the clinic, supporting STORM’s growth as the leading drug discovery company working on RNA modulating enzymes.
STORM has strengthened its team with the appointment of Dr Mark Albertella as VP Translational Oncology. Mark was previously Director of Biology at Medivir AB and has a successful track record in oncology drug discovery and development at Argenta, OSI Pharmaceuticals, Kudos and AstraZeneca, with over 20 years’ experience in biotech and pharma industry in the UK, US and Europe.